Correction to: J Headache Pain 22, 141 (2021)
https://doi.org/10.1186/s10194-021-01351-2
Following the publication of the original article [1], we were notified that the x-axis labels for part B of Figure 1 were incorrect in the previous version and had accidentally been duplicated from part A.
Originally published Figure 1:
Corrected Figures:
The original article has been corrected.
Reference
Nahas et al (2021) Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain 22:141. https://doi.org/10.1186/s10194-021-01351-2
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Nahas, S.J., Naegel, S., Cohen, J.M. et al. Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain 23, 57 (2022). https://doi.org/10.1186/s10194-022-01423-x
Published:
DOI: https://doi.org/10.1186/s10194-022-01423-x